ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0742

Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes

Natalie McCormick1, Chio Yokose2, Na Lu3 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA

Meeting: ACR Convergence 2023

Keywords: Administrative Data, Epidemiology, gout, Pharmacoepidemiology, prevention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Epidemiology & Public Health I

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure, and chronic kidney disease progression. Many trials have also found SGLT2i lower serum urate levels. However, data on gout risk are limited and the few available prior studies were not specific to those using metformin, the primary target populations of recent landmark trials like GRADE [GRADE Study Research Group, NEJM 2022;387:1075-88].

Our objective was to emulate recent clinical trials and compare incident gout risk among metformin-treated patients with type 2 diabetes initiating SGLT2i versus other second-line type 2 diabetes treatments (dipeptidyl peptidase 4 inhibitors [DPP-4i], glucagon-like peptide-1 receptor agonists [GLP1-RA], or sulfonylureas).

Methods: We performed a new user, active comparator, population-based cohort study using administrative health data for nearly all residents of British Columbia, Canada from Jan 2014 to June 2022, including all dispensed prescriptions, regardless of funder. A cohort of adults with type 2 diabetes using metformin (first-line therapy) was identified from ICD codes and dispensing data. Primary outcome was incident gout, defined as inpatient or outpatient diagnosis of gout plus dispensing of a gout medication (colchicine, corticosteroids, or NSAIDs) within 7 days, and no prior recorded gout diagnosis. We also stratified by sex, age, and baseline diuretic use.

Cox proportional hazards models were used with propensity score overlap weighting, stratified by calendar year of initiation. We also assessed for risk of genital infection (for which we expected SGLT2i would have a positive association), and for the risk of any osteoarthritis encounter, a negative control outcome for which we expected a null association.

Results: We included 27,791 type 2 diabetes patients in the SGLT2i vs. DPP-4i cohort (58% male, mean age 61), 19,875in the SGLT2i vs. GLP1-RA cohort (44% male, mean age 57), and 71,625in the SGLT2i vs. sulfonylurea cohort (60% male, mean age 59).Baseline characteristics, including diabetes duration and presence of complications, were well balanced between SGLT2i and comparators after overlap weighting (SMD < 0.1) (Table 1).Weighted hazard ratio (wHR) for incident gout associated with SGLT2i initiation was 0.54 (95% CI: 0.39, 0.74) vs. DPP-4i initiation, 0.39 (0.24, 0.62) for SGLT2i vs. GLP1-RA, and 0.61 (0.46, 0.80) for SGLT2i vs. sulfonylureas (Table 2).Results were consistent regardless of sex or age or baseline diuretic use.

For control outcomes, SGLT2i initiators had higher risk of genital infection than initiators of each comparator, as expected, while there was no difference in risk of osteoarthritis (Table 2).

Conclusion: SGLT2i initiation among metformin-treated patients with type 2 diabetes was associated with substantially lower risk of incident gout (i.e., primary prevention), compared with any other second-line option. Along with its known urate-lowering effects, as well as cardiovascular and survival benefits, SGLT2i could substantially reduce risk of incident gout for patients needing a second-line agent after metformin.

Supporting image 1

Table 1. Selected baseline characteristics among metformin-treated type 2 diabetes patients initiating SGLT2i vs. DPP_4i, GLP1-RA, or sulfonylureas, before and after propensity score overlap weighting.
* difference < 0.1 indicates negligible differences. n, number; y, years; SD, standard deviation; SGLT2i, sodium glucose cotransporter_2 inhibitors; DPP_4i, dipeptidyl peptidase 4 inhibitors; GLP1-RA, glucagon-like peptide_1 receptor agonists.

Supporting image 2

Table 2. Risk of incident gout and control outcomes among patients with type 2 diabetes treated with metformin, after propensity-score overlap weighting.
SGLT2i, sodium glucose cotransporter_2 inhibitor; DPP_4i, dipeptidyl peptidase 4 inhibitor; GLP1-RA, glucagon-like peptide_1 receptor agonist


Disclosures: N. McCormick: None; C. Yokose: None; N. Lu: None; H. Choi: Ani, 2, Horizon, 2, 5, LG, 2, Protalix, 2, Shanton, 2.

To cite this abstract in AMA style:

McCormick N, Yokose C, Lu N, Choi H. Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-of-incident-gout-associated-with-initiation-of-sodium-glucose-cotransporter-2-inhibitors-versus-other-second-line-agents-among-metformin-users-with-type-2-diabetes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-incident-gout-associated-with-initiation-of-sodium-glucose-cotransporter-2-inhibitors-versus-other-second-line-agents-among-metformin-users-with-type-2-diabetes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology